Paris , 29 May 2018 - Ipsen today announced that cabozantinib and irinotecan liposome injection are the subject of 8 presentations at the 2018 American Society of Clinical.
In his explanation of the tremelimumab priming dose, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, also reviews and analogizes checkpoint inhibitors as a whole.
Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, expands on findings that durvalumab plus tremelimumab demonstrated an overall survival benefit at 4 years for certain patients with unresectable hepatocellular carcinoma.